Please login to the form below

Not currently logged in
Email:
Password:

DVT

This page shows the latest DVT news and features for those working in and with pharma, biotech and healthcare.

Gilead, Galapagos JAK inhibitor clears phase II test

Gilead, Galapagos JAK inhibitor clears phase II test

DVT is a recognised side effect with Eli Lilly’s JAK1 inhibitor Olumiant (baricitinib), which finally made it to market for rheumatoid arthritis in Europe last year but was rejected in ... Gilead said that in the phase II AS trial the patient had an

Latest news

More from news
Approximately 9 fully matching, plus 43 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • FCB Halesway

    Eczema. BMS. Metastatic melanoma. Lung cancer. Boehringer Ingelheim. VTE prophylaxis. DVT/PE.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics